Compare VRT & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRT | REGN |
|---|---|---|
| Founded | N/A | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.2B | 73.9B |
| IPO Year | N/A | 1991 |
| Metric | VRT | REGN |
|---|---|---|
| Price | $149.48 | $751.73 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 23 |
| Target Price | $188.13 | ★ $795.74 |
| AVG Volume (30 Days) | ★ 7.3M | 1.1M |
| Earning Date | 10-22-2025 | 02-03-2026 |
| Dividend Yield | 0.16% | ★ 0.47% |
| EPS Growth | ★ 77.20 | 2.88 |
| EPS | 2.65 | ★ 41.59 |
| Revenue | $9,696,300,000.00 | ★ $14,247,800,000.00 |
| Revenue This Year | $28.77 | $1.95 |
| Revenue Next Year | $19.97 | $5.47 |
| P/E Ratio | $60.58 | ★ $17.94 |
| Revenue Growth | ★ 28.75 | 2.89 |
| 52 Week Low | $53.60 | $476.49 |
| 52 Week High | $202.45 | $790.98 |
| Indicator | VRT | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 33.83 | 60.13 |
| Support Level | $159.82 | $734.72 |
| Resistance Level | $185.41 | $757.35 |
| Average True Range (ATR) | 8.88 | 19.59 |
| MACD | -3.05 | -2.93 |
| Stochastic Oscillator | 4.71 | 61.46 |
Vertiv has roots tracing back to 1946 when its founder, Ralph Liebert, developed an air-cooling system for mainframe data rooms. As computers started making their way into commercial applications in 1965, Liebert developed one of the first computer room air conditioning, or CRAC, units, enabling the precise control of temperature and humidity. The firm has slowly expanded its data center portfolio through internal product development and the acquisition of thermal and power management products like condensers, busways, and switches. Vertiv has global operations today; its products can be found in data centers in most regions throughout the world.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).